VERTEX PHARMACEUTICALS INCORPORATED
Lobbying client. Federal LDA filings.
Connected on the graph
Inbound (27)
| date | from | type | amount | role | source |
|---|---|---|---|---|---|
| β | Kate Kalutkiewicz | lobbied_for | β | lda_lobbyist_client | |
| β | Matthew O Schumaker | lobbied_for | β | lda_lobbyist_client | |
| β | Joshua David Odintz | lobbied_for | β | lda_lobbyist_client | |
| β | Swarna Vallurupalli | lobbied_for | β | lda_lobbyist_client | |
| β | Kyle Hill | lobbied_for | β | lda_lobbyist_client | |
| β | Adam Buckalew | lobbied_for | β | lda_lobbyist_client | |
| β | Adam Buckalew | lobbied_for | β | lda_lobbyist_client | |
| β | Hazen Clay Marshall | lobbied_for | β | lda_lobbyist_client | |
| β | Michael Hayes | lobbied_for | β | lda_lobbyist_client | |
| β | Laura Friedel | lobbied_for | β | lda_lobbyist_client | |
| β | Veronica Jackson | lobbied_for | β | lda_lobbyist_client | |
| β | Hannah Beth Cornwell | lobbied_for | β | lda_lobbyist_client | |
| β | Monica Popp | lobbied_for | β | lda_lobbyist_client | |
| β | Andrew Joseph Siracuse | lobbied_for | β | lda_lobbyist_client | |
| β | Mike Mckay | lobbied_for | β | lda_lobbyist_client | |
| β | E. Brandon Garrett | lobbied_for | β | lda_lobbyist_client | |
| 2026-01-01 | ALSTON & BIRD LLP | lobbies_for | β | lda_filing | |
| 2026-01-01 | VERTEX PHARMACEUTICALS INCORPORATED | lobbies_for | $1,140,000 | lda_filing | |
| 2026-01-01 | HOLLAND & KNIGHT LLP | lobbies_for | $20,000 | lda_filing | |
| 2026-01-01 | MARSHALL & POPP, LLC | lobbies_for | $60,000 | lda_filing | |
| 2026-01-01 | ALB SOLUTIONS | lobbies_for | β | lda_filing | |
| 2026-01-01 | ALB SOLUTIONS | lobbies_for | $50,000 | lda_filing | |
| 2026-01-01 | EMPIRE CONSULTING GROUP | lobbies_for | $50,000 | lda_filing | |
| 2026-01-01 | SALT POINT STRATEGIES | lobbies_for | $10,000 | lda_filing | |
| 2025-01-01 | MARSHALL & POPP, LLC | lobbies_for | β | lda_filing | |
| 2025-01-01 | SALT POINT STRATEGIES | lobbies_for | β | lda_filing | |
| 2025-01-01 | MCLARTY INBOUND LLC | lobbies_for | β | lda_filing |
Outbound (8)
| date | type | to | amount | role | source |
|---|---|---|---|---|---|
| 2026-01-01 | lobbies_on_bill | HR 1227 β Alternatives to PAIN Act | β | H.R. 1227 | lobbying_bill_mention |
| 2026-01-01 | lobbies_on_bill | HR 1414 β Cameronβs Law | β | H.R. 1414 | lobbying_bill_mention |
| 2026-01-01 | lobbies_on_bill | HR 1518 β New Era of Preventing End-Stage Kidney Disease Act | β | H.R. 1518 | lobbying_bill_mention |
| 2026-01-01 | lobbies_on_bill | HR 6423 β HELP Copays Act | β | H.R. 6423 | lobbying_bill_mention |
| 2026-01-01 | lobbies_on_bill | S 475 β Alternatives to PAIN Act | β | S. 475 | lobbying_bill_mention |
| 2026-01-01 | lobbies_on_bill | HR 1227 β Alternatives to PAIN Act | β | H.R. 1227 | lobbying_bill_mention |
| 2026-01-01 | lobbies_on_bill | S 475 β Alternatives to PAIN Act | β | S.475 | lobbying_bill_mention |
| 2026-01-01 | lobbies_on_bill | HR 1227 β Alternatives to PAIN Act | β | HR 1227 | lobbying_bill_mention |
- Source id
188223- State
- MA
- Country
- US
- Principal place of business
- US
- Government-entity client
- false
- Effective date
- 2008-02-14
- Total spend (across 1 ingested filings)
- $0
Filings
| Posted | Type | Year | Lobbying firm | Income |
|---|---|---|---|---|
| 2026-04-17 | Q1 | 2026 | VERTEX PHARMACEUTICALS INCORPORATED | β |